on Immunic AG
Immunic, Inc. to Announce Financial Results for Q2 2024 and Provide Corporate Update
NEW YORK, August 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company specializing in orally administered therapies for chronic inflammatory and autoimmune diseases, will disclose its financial results for the second quarter ended June 30, 2024, on August 8, 2024. The announcement will be made ahead of the U.S. financial markets opening, followed by a webcast at 8:00 am ET.
To join the webcast, participants are asked to register beforehand either via the provided Zoom link or through Immunic’s official website. A replay will be accessible approximately an hour post-event on the company's website.
Immunic is advancing several clinical programs, including vidofludimus calcium (IMU-838) and IMU-856, aimed at treating multiple sclerosis and gastrointestinal diseases respectively. Each program is progressing through various developmental phases, demonstrating promising results in preclinical and clinical trials.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Immunic AG news